Form 4 for MRK Merck & Co.
Accepted 2026-01-28 00:00:00 ET · period of report 2026-01-26 · accession 0000310158-26-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-28 | 2026-01-26 | MRK | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $107.40 | +20.5K | 102.3K | +25% | +$2.20M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-26 | A | A | 20,469 | $107.40 | 102,270.05 | D | — | — | (F1) Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. (F2) Holdings include shares acquired in dividend reinvestment transactions. |